Healthcare
Ironwood Pharmaceuticals, Inc.(IRWD)
Live Price
Offline$3.68
+0.55% today
1Y Change
+388.00%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $720.00M
- Revenue Growth
- -15.7%
- EPS Growth
- +2627.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ironwood Pharmaceuticals, Inc. (IRWD) is a Healthcare stock with a market cap of $720.00M and listed on NASDAQ. The stock last traded around $3.68 and up 388.0% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -15.7%, EPS growth of +2627.3%, a dividend yield of 0.0%. What stands out right now is revenue -15.7%, EPS +2627.3%, free cash flow +22.8% with operating margin 33.2% and ROIC 9.4%. Valuation is more restrained than many high-expectation growth names at P/E 29.7 and price/sales 2.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IRWD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-15.7% vs +7.6% peer median
Operating Margin
Above sector median
+33.2% vs +19.4% peer median
P/E
Below sector median
29.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -15.7% and EPS is at +2627.3%, with operating margin around 33.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -13.7% | -23.8% | -29.6% |
2026 Feb 25, 2026 | -150.0% | +8.9% | +11.3% | -5.1% |
2025 Nov 10, 2025 | +166.7% | +14.2% | +23.7% | +42.7% |
Benchmark Edge
IRWD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IRWD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IRWD Max Drawdown
-43.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IRWD and SPY.
Company Overview
Ironwood Pharmaceuticals, Inc.
NASDAQ Global Select
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
- Leadership
- Thomas A. McCourt
- IPO Date
- Feb 3, 2010
- Employees
- 253
- Street Address
- 100 Summer Street
- Mailing
- Boston, MA, 02110
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 621 7722
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.7
- EV/EBITDA
- 9.0
- Price/Sales
- 2.4
- Price/Book
- โ
Growth
- Revenue
- -15.7%
- EPS
- +2627.3%
- Free Cash Flow
- +22.8%
Profitability
- Gross Margin
- 90.6%
- Operating Margin
- 33.2%
- Net Margin
- 8.1%
- ROE
- -8.2%
- ROIC
- 9.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.